about
Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers.Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based PerspectiveMouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control regionAntibody-based therapies in multiple myelomaConcordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsEmerging drugs for the management of cancer treatment induced bone loss.Functions of nuclear factor kappaB in bone.Denosumab and the current status of bone-modifying drugs in breast cancer.Denosumab for the management of bone disease in patients with solid tumors.Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.The role of palliative external beam radiation therapy in boney metastases pain management.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.Macrophages and skeletal health.Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.Medication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors.
P2860
Q35001309-D175FC91-77FD-4AFF-B242-EC1CE09AB17DQ35025528-3F9C8FB8-81ED-47E5-B5FB-D3B620F1E1D1Q35063276-5E4B8665-95A1-4EF3-8ABB-50682489BAC1Q35431150-4F275CBF-AC5B-4FFE-A02F-C5C11BFD54C9Q36158922-90C5788C-D1E0-4B16-B27A-ED641089B3E3Q37727235-60F01B72-3427-4D82-8027-4FEEBC6A52D6Q37730952-F86DDB22-A7CD-4D71-9F10-29A2EC60CD0EQ37965768-A0BA0BCE-8E5A-43E5-87A3-01627DA47F57Q37970800-AFE01CEC-2EF0-40BE-ABDE-791CEB1E5349Q37982190-F02991CF-F69D-4293-BFFC-845823B967F7Q38029995-4B637A6A-E700-410C-8518-1B793A05AB72Q38080150-D9FFF709-F56A-4AD1-80B7-DD458C586C75Q38090691-2F8C3D7C-A29D-47FA-BA39-4D44ACBF9FB5Q38205856-FCD1D8D6-E8EA-4F87-81F9-7E6ACE9D3304Q38331262-AF47DA2E-A287-4913-8F0C-EDE29BC595FEQ39129914-EA527D15-9C60-4D99-9AF8-DDC21CE7A482Q39170948-BD7BEDB3-6178-403A-91B4-3E097FF209BDQ42324262-E39DBF86-EB0E-4777-859E-918F1EC9DF02Q47221234-C2A673DE-408A-4908-ACB2-AEBF815EEB0CQ52757516-3021673E-EAC0-4DC3-A070-DB3C5F7EFF53
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Denosumab in osteoporosis and oncology.
@en
Denosumab in osteoporosis and oncology.
@nl
type
label
Denosumab in osteoporosis and oncology.
@en
Denosumab in osteoporosis and oncology.
@nl
prefLabel
Denosumab in osteoporosis and oncology.
@en
Denosumab in osteoporosis and oncology.
@nl
P2093
P2860
P356
P1476
Denosumab in osteoporosis and oncology.
@en
P2093
Jill S Burkiewicz
Sarah L Scarpace
Susan P Bruce
P2860
P304
P356
10.1345/APH.1M102
P407
P577
2009-07-21T00:00:00Z